76.86

0.05% 0.035

Forte Biosciences Inc (FBRX)

Overview News Price History Option Chain Financials Discussions Forecast

Forte Biosciences Inc stock is traded at $76.86, with a volume of 408.04K. It is up +0.05% in the last 24 hours and up +57.33% over the past month. Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Previous Close:

$76.83

Open:

$76.85

24h Volume:

408.04K

Relative Volume:

0.38

Market Cap:

$1.63B

Revenue:

Net Income/Loss:

$-75.86M

P/E Ratio:

-15.05

EPS:

-5.1069

Net Cash Flow:

$-59.39M

1W Performance:

+0.07%

1M Performance:

+57.33%

6M Performance:

+158.13%

1Y Performance:

+564.39%

1-Day Range:

$76.84

$76.89

1-Week Range:

$76.76

$76.90

52-Week Range:

$10.11

$77.20

Forte Biosciences Inc Stock (FBRX) Company Profile

Name

Forte Biosciences Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(310) 618-6994

Address

3060 PEGASUS PARK DRIVE, DALLAS, CA

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

FBRX's Discussions on Twitter

Compare FBRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FBRX Forte Biosciences Inc	76.87	1.63B	0	-75.86M	-59.39M	-5.1069
VRTX Vertex Pharmaceuticals Inc	515.63	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.01	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.71	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.05	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.46	39.31B	5.76B	514.49M	1.10B	4.4813

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Initiated	Evercore ISI	Outperform
Aug-18-25	Initiated	Guggenheim	Buy
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Truist	Buy → Hold
May-14-21	Initiated	B. Riley Securities	Buy
Mar-26-21	Initiated	Citigroup	Buy
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-25-20	Initiated	Truist	Buy

View All

Forte Biosciences Inc Stock (FBRX) Latest News

Aug 16, 2026

Forte Biosciences (NASDAQ:FBRX): What Will the Market Learn About Development Strategy? - Kalkine Media

Aug 16, 2026

Avoiding Lag: Real-Time Signals in (FBRX) Movement - Stock Traders Daily

Aug 16, 2026

Aug 15, 2026

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results - simplywall.st

Aug 15, 2026

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com

Aug 15, 2026

Aug 14, 2026

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77 - Moomoo

Aug 13, 2026

Forte Biosciences (FBRX) gains 5.6% stake holder in Affinity Asset Advisors - Stock Titan

Aug 13, 2026

Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook - AD HOC NEWS

Aug 13, 2026

FBRX SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus

Aug 13, 2026

Aug 12, 2026

FORTE BIOSCIENCES ($FBRX) Releases Q2 2026 Earnings - Quiver Quantitative

Aug 12, 2026

Forte Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Successful Equity Raise - Kalkine Media

Aug 12, 2026

Forte Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS - marketbeat.com

Aug 12, 2026

Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal - Stock Titan

Aug 12, 2026

Forte Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

Aug 11, 2026

Forte Biosciences (FBRX) investor Glazer Capital now holds 1.46% stake - Stock Titan

Aug 11, 2026

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences - Yahoo Finance

Aug 11, 2026

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc.FBRX - Business Wire

Aug 11, 2026

Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? - Sahm

Aug 11, 2026

Aug 10, 2026

argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition - Yahoo Finance

Aug 10, 2026

Forte Biosciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView

Aug 10, 2026

FBRX Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Aug 10, 2026

Aug 08, 2026

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent

Aug 08, 2026

Aug 07, 2026

Janus Henderson Group Ltd. (NASDAQ: FBRX) discloses 2.5% beneficial stake in Forte - Stock Titan

Aug 07, 2026

Aug 06, 2026

Argenx Announces Commencement Of Tender Offer To Acquire Forte Biosciences, Inc. >ARGX.BT - Moomoo

Aug 06, 2026

argenx launches tender offer for Forte Biosciences at $77 per share - Investing.com

Aug 06, 2026

Forte Biosciences (NASDAQ:FBRX) Sees Large Volume IncreaseHere's Why - MarketBeat

Aug 06, 2026

Argenx Unit Launches Tender Offer to Acquire Forte Biosciences - marketscreener.com

Aug 06, 2026

Argenx Unit Kicks Off Tender Offer to Buy Forte Biosciences - marketscreener.com

Aug 06, 2026

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. - GlobeNewswire

Aug 06, 2026

Forte Biosciences (FBRX) to Release Earnings on Thursday - MarketBeat

Aug 06, 2026

Aug 03, 2026

Weekly Recap: Argenx $2.2B buyout at $77 and FB102 84% response rate - TradingView

Aug 03, 2026

Janus Henderson Group PLC Reduces Stake in Forte Biosciences, Inc. $FBRX - marketbeat.com

Aug 03, 2026

Aug 01, 2026

Price to earnings forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView

Aug 01, 2026

Enterprise value to revenue forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView

Aug 01, 2026

Jul 31, 2026

argenx SE (ARGX) Forte Biosciences, Inc.M&A CallSlideshow (NASDAQ:ARGX) 2026-07-31 - Seeking Alpha

Jul 31, 2026

Jul 30, 2026

Forte Biosciences stock hits 52-week high at 76.69 USD By Investing.com - Investing.com Nigeria

Jul 30, 2026

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement - Barchart.com

Jul 30, 2026

Jul 29, 2026

Forte Biosciences (NASDAQ:FBRX) Stock Rating Lowered by Evercore - marketbeat.com

Jul 29, 2026

Jul 28, 2026

Netherlands: argenx to acquire Forte Biosciences for US$2.2bn - Investors in Healthcare

Jul 28, 2026

Barclays cuts Forte Biosciences stock rating on acquisition terms By Investing.com - Investing.com Nigeria

Jul 28, 2026

argenx signs agreement to buy Forte Biosciences for $2.2bn - Yahoo Finance

Jul 28, 2026

Biotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SE - QuotedData

Jul 28, 2026

Barclays cuts Forte Biosciences stock rating on acquisition terms - Investing.com

Jul 28, 2026

Forte Biosciences (FBRX) Stock Looks Stretched On Book Value Yet Strong On Pipeline Hope - simplywall.st

Jul 28, 2026

Biotech Growth Trust Notes $2.2 Billion Acquisition Of Forte Biosciences - DirectorsTalk Interviews

Jul 28, 2026

argenx acquires Forte Biosciences for FB102 - BioXconomy

Jul 28, 2026

Jul 27, 2026